NOT-CA-20-079: Notice of NCI's Participation in PA-20-047, Development of Highly Innovative Tools and Technology for Analysis of Single Cells (SBIR) (R43/R44 Clinical Trial Not Allowed)

Notice of NCI's Participation in PA-20-047, Development of Highly Innovative Tools and Technology for Analysis of Single Cells (SBIR) (R43/R44 Clinical Trial Not Allowed)

Notice Number:

NOT-CA-20-079

Key Dates

Release Date:

July 2, 2020

Related Announcements

PA-20-047 - Development of Highly Innovative Tools and Technology for Analysis of Single Cells (SBIR) (R43/R44 Clinical Trial Not Allowed)

Issued by

National Cancer Institute (NCI)

Purpose

The purpose of this notice is to inform potential applicants that the National Cancer Institute (NCI) will participate, effective immediately, in PA-20-047, Development of Highly Innovative Tools and Technology for Analysis of Single Cells (SBIR) (R43/R44 Clinical Trial Not Allowed)

The following changes and updates are made to PA-20-047 (shown in italics) to reflect NCI’s participation in this Funding Opportunity Announcement (FOA).

I. Part 1. Overview Information

Participating Organization(s)
National Institutes of Health (NIH)

Components of Participating Organizations
National Institute of Mental Health (NIMH)

National Eye Institute (NEI)

National Human Genome Research Institute (NHGRI)

National Institute of Dental and Craniofacial Research (NIDCR)

National Institute on Drug Abuse (NIDA)

National Institute of Environmental Health Sciences (NIEHS)

National Institute of General Medical Sciences (NIGMS)

National Center for Advancing Translational Sciences (NCATS)

National Cancer Institute (NCI)

II. Catalog of Federal Domestic Assistance (CFDA) Number(s)
93.242, 93.113, 93.859, 93.867, 93.350, 93.121, 93.279, 93.172, 93.393, 93.394, 93.395, 93.396

III. Part 2. Full Text of Announcement, Section I. Funding Opportunity Description

Under Interests of the Institutes and Centers

Currently Reads

NIMH
The NIMH intends to support the development of single cell technologies to advance the mission of the Institute as described in the NIMH Strategic Plan. In particular the NIMH is interested in the next-generation approaches that can or have the potential to distinguish heterogeneous states of brain cells in mammalian and human brain samples (e.g., NIH NeuroBioBank).

NCATS
NCATS intends to fund applications under this FOA that meet its mission. For a description of the NCATS SBIR/STTR research priorities, please refer to http://ncats.nih.gov/smallbusiness/priorities.

NIDA
NIDA supports research to understand, prevent, and treat substance use disorders and mitigate their consequences to public health. For this FOA, NIDA encourages basic and/or clinical collaborative research to promote the understanding of mechanisms of neuronal differentiation, neural circuit formation and modulation, synaptic formation, trimming and activities, as well as related events of brain development pertinent to substances of abuse, including but not limited to nicotine, amphetamine, cocaine, opiates, barbiturates, cannabinoids, and hallucinogens. Specifically, for this FOA, NIDA is interested in the identification of genetic and epigenetic effects on the development and function of the nervous system, as well as novel approaches to elucidate the processes and genetic mechanisms involved in the development of brain regions, neural circuits, and neurotransmitter systems mediating the addictive properties of drugs of abuse to inform future prevention and treatment of substance use disorders. Please note: NIDA does not support Phase IIB applications, or Phase IIB research, for this announcement.

NIGMS
NIGMS supports basic biomedical research and research training that contributes to the understanding of fundamental cellular and physiological principles, and specific clinical areas (i.e., clinical pharmacology, trauma and burn injury, sepsis, wound healing, and anesthesiology) contained within the mission of NIGMS.

NIEHS
NIEHS supports research on how the environment affects people in order to promote healthier lives. For this FOA, NIEHS is interested in tools and technologies to detect responses to environmental stressors in heterogeneous populations of cells, approaches to detect effects of environmental stress on germ cells, and technologies to isolate or detect effects in stem or progenitor cells. Please see the NIEHS Program Descriptions and Research Topics for more detailed information.

NEI
The NEI supports biomedical research and research training to understand the visual system, a major component of the human brain. Loss of neurons or various cell types in the retina or the brain can cause visual impairment. NEI is interested in applications for the development of novel tools/technologies with single cell resolution that can improve our understanding in all cell types in the visual system, and how they connect with each other. For a description of the NEI SBIR/STTR research priorities, please refer to https://nei.nih.gov/funding/smallbusiness_nei

NHGRI
Through this FOA, NHGRI is especially interested in supporting applications that address: (1) measurement of chromatin features, and simultaneous measurement of chromatin features and transcriptomic responses in human tissue in high throughput, (2) spatially resolved genomic measurements in situ, (3) development of robust analytical methods for integration of diverse genomic data modalities, QA/QC, normalization and other methods that improve analytical pipelines for genomics.

Modified to Read

NIMH
The NIMH intends to support the development of single cell technologies to advance the mission of the Institute as described in the NIMH Strategic Plan. In particular, the NIMH is interested in the next-generation approaches that can or have the potential to distinguish heterogeneous states of brain cells in mammalian and human brain samples (e.g., NIH NeuroBioBank).

NCI

Tumors are highly heterogeneous at the cellular, molecular, and genetic levels. Through this FOA, the NCI is especially interested in applications requesting support for research on novel tools/technologies that enable the characterization of this heterogeneity among cells in situ or in clinically relevant samples and for clinically testing drug combinations and resistance with minimal invasiveness. These tools/ technologies include but are not limited to multidimensional single cell imaging, single cell mass cytometry, and high throughput technologies for isolation and characterization of DNA and RNA from individual cells either in situ or in clinically relevant samples.

IV. Section VII. Agency Contacts

Scientific/Research Contact(s)

Currently Reads

Margaret Grabb, Ph.D.
National Institute of Mental Health (NIMH)
Telephone: 301-443-3563
Email: mgrabb@mail.nih.gov

Ajay Pillai, Ph.D.
National Human Genome Research Institute (NHGRI)
Telephone: 301-496-7531
Email: ajay.pillai3@nih.gov

Daniel Shaughnessy, Ph.D.
National Institute of Environmental Health Sciences (NIEHS)
Telephone: 984-287-3321
Email: shaughn1@niehs.nih.gov

Paek Lee, Ph.D.
National Eye Institute (NEI)
Telephone: 301-451-2020
Email: paek.lee@nih.gov

Lillian Shum, Ph.D.
National Institute of Dental and Craniofacial Research (NIDCR)
Telephone:301-594-0618
Email: shuml@mail.nih.gov

Lili Portilla, Ph.D.
National Center for Advancing Translational Sciences (NCATS)
Telephone: 301-827-7170
Email: portilll@mail.nih.gov

Dmitriy Krepkiy, Ph.D.
National Institute of General Medical Sciences (NIGMS)
Telephone: 301-435-0752
Email: krepkiyd@mail.nih.gov

Da-Yu Wu, Ph.D
National Institute on Drug Abuse (NIDA)
Telephone: 301-435-4649
Email: wudy@nida.nih.gov